Evidence map›Paper›PMID 35509638›Full record

ArticleJBMR plus2022

Yangjin Bae, Huan-Chang Zeng, Yi-Ting Chen, Shamika Ketkar, Elda Munivez, Zhiyin Yu, Francis H Gannon, Brendan H Lee

Open access · goldAbstract read
In one paragraph

Article in JBMR plus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Involvement ofFrontiers in oncology · 2025
    Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. NOTCH Signaling in Osteosarcoma.Current issues in molecular biology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Yangjin BaeDepartment of Molecular and Human Genetics Baylor College of Medicine Houston TX USA.ORCID https://orcid.org/0000-0003-2397-0192
Huan-Chang ZengDepartment of Molecular and Human Genetics Baylor College of Medicine Houston TX USA.
Yi-Ting ChenIntegrative Molecular and Biomedical Sciences Program Baylor College of Medicine Houston TX USA.
Shamika KetkarDepartment of Molecular and Human Genetics Baylor College of Medicine Houston TX USA.
Elda MunivezDepartment of Molecular and Human Genetics Baylor College of Medicine Houston TX USA.
Zhiyin YuDepartment of Molecular and Human Genetics Baylor College of Medicine Houston TX USA.
Francis H GannonDepartment of Pathology and Immunology Baylor College of Medicine Houston TX USA.
Brendan H LeeDepartment of Molecular and Human Genetics Baylor College of Medicine Houston TX USA.ORCID https://orcid.org/0000-0001-8573-4211
Baylor College of Medicine · US

Funding

UNDERSTANDING FXTAS AMONG MALES WITH THE FMR1 PREMUTATIONP30HD024064 · NICHD · BAYLOR COLLEGE OF MEDICINE · PI TOLIAS, KIMBERLY R · 1988 to 2013
$29.4M
Preclinical and Clincial OutcomesP50HD103555 · NICHD · BAYLOR COLLEGE OF MEDICINE · PI MIRJANA MALETIC-SAVATIC · 2020 to 2026
$9.9M
Steps towards a paternal gene activation therapy for Angelman syndromeU54HD083092 · NICHD · BAYLOR COLLEGE OF MEDICINE · PI NELSON, DAVID LOREN, SAMACO, RODNEY C · 2014 to 2019
$7.8M
NICHD NIH HHS P30 HD024064NICHD NIH HHS P50 HD103555NICHD NIH HHS U54 HD083092
6 · The paper itself

Abstract

The expression of microRNAs (miRNAs) is dysregulated in many types of cancers including osteosarcoma (OS) due to genetic and epigenetic alterations. Among these,

Indexed as

E2F5miRNA‐34cNotchOsteosarcomaTumor suppressor

Identifiers

PMID35509638
PMCPMC9059472
OpenAlexW4225986562

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.